secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evoke Pharma Inc (—)
CIK:        0001403708
Form:       8-K
Filed at:   2023-11-29T23:59:59+00:00
Accession:  0000950170-23-066558
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Evoke Pharma faces Nasdaq delisting; hearing set for March 7, 2024
------------------------------------------------------------------

- Received Nasdaq notice on Nov 21 for non-compliance with Minimum Stockholders' Equity Requirement of $2.5M.
- Hearing before Nasdaq Hearings Panel scheduled for March 7, 2024; delisting action stayed pending outcome.
- Company exploring options including raising capital, but no assurance of regaining compliance.
- Non-compliance risk could lead to transfer to OTC markets if delisted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1403708/000095017023066558/0000950170-23-066558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1403708/000095017023066558/evok-20231127.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-066558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer